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Abstract
Two variants (A and B) of the widely employed Walker 256 rat tumor
cells are known. When inoculated sc, the A variant produces solid,
invasive, highly metastasizing tumors that cause severe systemic
effects and death. We have obtained a regressive variant (AR) whose
sc growth is slower, resulting in 70-80% regression followed by
development of immunity against A and AR variants. Simultaneously
with the beginning of tumor regression, a temporary anemia devel-
oped (~8 days duration), accompanied by marked splenomegaly
(~300%) and changes in red blood cell osmotic fragility, with mean
corpuscular fragility increasing from 4.1 to 6.5 g/l NaCl. The possibil-
ity was raised that plasma factors associated with the immune response
induced these changes. In the present study, we identify and compare
the osmotic fragility increasing activity of plasma fractions obtained
from A and AR tumor bearers at different stages of tumor develop-
ment. The results showed that by day 4 compounds precipitating in
60% (NH4)2SO4 and able to increase red blood cell osmotic fragility
appeared in the plasma of A and AR tumor bearers. Later, these
compounds disappeared from the plasma of A tumor bearers but
slightly increased in the plasma of AR tumor bearers. Furthermore, by
day 10, compounds precipitating between 60 and 80% (NH4)2SO4 and
with similar effects appeared only in plasma of AR tumor bearers. The
salt solubility, production kinetics and hemolytic activity of these
compounds resemble those of the immunoglobulins. This, together
with their preferential increase in rats bearing the AR variant, suggest
their association with an immune response against this tumor.
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Introduction
The Walker 256 (W256) tumor cells have
been extensively used in studies of cancer
pathophysiology (1-4). Two variants of this
tumor have been reported, namely A and B
(3). The A variant has been widely em-
ployed. It is known that tumor variants can
be obtained by repeated passages through
different media, a phenomenon that can be
reversed by successive passages through the
original medium (5). In our laboratory, after
60 successive intraperitoneal (ip) passages,
a regressive variant (AR) of the W256 A
tumor was obtained. The subcutaneous (sc)
unifocal growth of the AR tumor variant is
slower when compared to the A variant, and
in 70-80% of the individuals tumor regres-
sion occurs followed by development of im-
munity against both the A and AR variants
(Rettori O, Vieira-Matos AN, Guimarães F
and Cavalcanti TC, unpublished data). Simi-
lar examples of the development of immu-
nogenic variants of several tumors can be
found in the literature (6).
Previous studies of the host’s response to
the AR variant have shown that 8 to 12 days
after unifocal inoculation and preceding overt
tumor regression, a temporary anemia al-
ways develops, followed by an increase in
red blood cell (RBC) osmotic fragility, a
marked hypertrophy of the spleen (7) and
presence in plasma of a substance able to
increase the osmotic fragility of healthy RBC
(Rettori O, Vieira-Matos AN, Guimarães F
and Cavalcanti TC, unpublished data). Sple-
nectomy always greatly augmented the lev-
els of anemia, with a further increase in RBC
osmotic fragility. The hemolytic mechanism
of the anemia and its early and temporary
manifestation (both suggesting the involve-
ment of polyclonal immunoglobulins), the
apparent role of the spleen in modulating its
evolution and the fact that it appeared only in
the rats bearing the AR tumor variant raised
the possibility that factors appearing in the
plasma, associated with the immune response,
could be responsible for the increase in RBC
osmotic fragility observed in rats bearing the
AR tumor variant, and that splenectomized
tumor bearers could be a convenient source
of these factors.
Considerable difficulty in experimental
cancer studies, which usually employ uni-
focal tumor inoculations, is related to the
fact that the initiation of the systemic effects
of cancer in individuals of the same group is
a random phenomenon. It may start any time
between 6 and 47 days or more after tumor
inoculation, with deaths occurring between
days 14 and 58 or more (7). By employing
multifocal simultaneous sc inoculations (2,
4 or more inoculations/rat), the beginning of
the systemic effects of cancer is rapid and
highly synchronized among individuals of
the same group, beginning 3-5 days after
tumor cell inoculation and leading to death
within 10-13 days (7-9). Therefore, studies
employing multifocal inoculations yield rapid
and highly reproducible results.
The purpose of the present study was to
partially characterize the putative plasma
factors responsible for the increase in RBC
osmotic fragility in AR tumor-bearing rats.
For this purpose, we monitored the time
course of appearance of increasing RBC
osmotic fragility activity in fractions ob-
tained from plasma of splenectomized rats
receiving multifocal inoculations of the A
and AR variants of W256 tumor cells.
Material and Methods
Experimental design
After splenectomy under ether anesthe-
sia, the rats were randomly divided into three
groups of 6 rats each: control, A tumor bear-
ers, and AR tumor bearers. Twenty-four to
48 h later (day zero), all rats were inoculated
sc under slight ether anesthesia. Control rats
received 250 µl Ringer-lactate solution em-
ployed to dilute the tumor cells, and rats in
the experimental groups (A and AR) re-
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ceived the same amount of Ringer-lactate
containing the appropriate tumor cells. Be-
fore tumor inoculation, 0.7 ml blood was
collected from the suborbital plexus into a
syringe containing 0.05 ml heparin (5000
IU/ml). A similar blood sample was also
obtained on day 4 after the inoculations. On
day 10, all animals were sacrificed under
anesthesia and a large blood sample was
collected following thoracotomy, iv heparin
injection and heart section. Hemoglobin lev-
els and the osmotic fragility of fresh RBC
were also determined in all blood samples.
On days 0, 4 and 10 after the inoculations,
pools of plasma from 6 animals were ob-
tained. One aliquot of each pool was frozen
(-18ºC) for further testing of its effect on
healthy RBC osmotic fragility, and the re-
mainder was used in ammonium sulfate pre-
cipitation studies. Finally, the effect of the
plasma and its fractions on RBC osmotic
fragility was tested employing fresh RBC
from normal donors as described below.
Tumor and animals
The W256 A tumor line was provided by
Dr. Maria C. Cintra Gomes of the Departa-
mento de Fisiologia, Instituto de Biologia,
UNICAMP. The line originally came from
the National Cancer Institute Bank, Cam-
bridge, MA, USA. This tumor and its AR
variant are stored under liquid N2, and main-
tained by ip or sc passage in rats.
Eight-week-old male Wistar rats were
used in this study. The animals were housed
(5 per cage) at controlled room temperature
(21º ± 2ºC) on a 12-h light-dark cycle. Ani-
mals were allowed free access to standard rat
chow (Labina/Purina, Campinas, SP, Brazil)
and water. The rats were splenectomized
and then randomly divided into 3 groups: a)
controls (N = 6), b) W256 A variant tumor
bearers (A, N = 6), and c) W256 AR variant
tumor bearers (AR, N = 6). Each tumor-
bearing rat received multifocal simultaneous
sc inoculations at four dorsal sites, spaced at
least 1 cm apart, with 5 × 106 tumor cells (A
or AR) suspended in 250 µl Ringer-lactate,
in each site. The controls received identical
inoculations of Ringer-lactate (placebo).
Plasma pools (6 animals/pool) were used in
the ammonium sulfate fractionation studies.
Tumor cells with 98% viability assessed by
Trypan blue were obtained from the ascitic
fluid of donor rats. General United Kingdom
Coordinating Committee on Cancer Research
guidelines for animal welfare were followed
(10).
Ammonium sulfate fractionation of plasma
proteins
Ammonium sulfate was slowly added to
the pool of total plasma (2.0-5.0 ml, diluted
1/10 in PBS) immediately after collection
from control and tumor-bearing rats under
constant stirring to a final concentration of
60%, w/v (11). Stirring was maintained for
another 60 min and the solution was then
centrifuged at 375 g for 30 min. The super-
natant and precipitates were named S60 and
P60, respectively. The ammonium sulfate
concentration of the S60 fractions was in-
creased to 80% to obtain a P80 fraction by
centrifugation as described earlier. The P60
and P80 fractions were resuspended in 2.0 to
5.0 ml of 10 mM PBS, pH 7.4. Finally, all
fractions were extensively dialyzed against
PBS for 48 h with six buffer changes. Samples
were diluted in PBS or concentrated with a
10-kDa molecular membrane (Spectrum, type
C, POR, Houston, TX, USA) to reconsti-
tute the original volumes. All operations were
carried out on ice at ± 4ºC. The protein
content of the different fractions was meas-
ured by the method of Lowry et al. (12).
Determination of hemoglobin and RBC
osmotic fragility
Hemoglobin and RBC osmotic fragility
were determined by the method of Dacie et
al. (13). For practical purposes, mean cor-
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puscular fragility was employed for data anal-
ysis of RBC osmotic fragility defined as the
NaCl concentration (g/l) causing 50% RBC
lysis (13).
RBC incubation tests
RBC from normal rats were used to test
the osmotic fragility changes induced by the
putative factors present in the plasma and its
fractions from tumor bearers. After the cen-
trifugation of blood, 150 µl of normal packed
RBC was resuspended (final hematocrit:
~20%) and incubated at 37ºC for 30, 120 and
240 min in 0.6 ml of the following solutions:
a) plasma from splenectomized controls; b)
plasma from A tumor bearers; c) plasma
from AR tumor bearers; d) fractions S60
control, A or AR; e) fractions P60 control, A
or AR; f) fractions P80 control, A or AR; g)
autologous plasma from RBC donors and
last change dialysis buffer as controls. Be-
fore incubation, in order to achieve a glucose
concentration of ~150 mg/100 ml, 3.5 µl of
25% glucose was added to the solutions
lacking glucose (dialysis buffer and dialyzed
fractions).
Autopsy
Autopsies were performed in all tumor-
bearing rats. Special attention was paid to
the eventual presence of metastases, signifi-
cant tissue invasion and bleeding.
Statistical analysis
The results are reported as means ± SEM
and means(diff) ± SEM(diff) when analyzing
paired data. Statistical significance was de-
termined by ANOVA followed by the post
hoc Dunnett test (P < 0.05), and by the paired
Student t-test.
Results
Development of anemia
Although there were no changes on day 4,
ten days after tumor inoculation (11-12 days
after splenectomy), hemoglobin levels dropped
markedly in tumor bearers, from 15.2 ± 0.5 to
Figure 1. Development of ane-
mia by splenectomized rats in-
oculated multifocally with A and
AR Walker 256 (W256) tumor
cells. Tumor cells (5 x 106) were
simultaneously inoculated sc in
four dorsal sites at least 1 cm
apart. Data are reported as
means ± SEM. The number of
rats in each group is given in
parentheses. *P < 0.01 com-
pared to control on day 10
(paired Student t-test).
Figure 2. Changes of osmotic
fragility of fresh RBC from sple-
nectomized rats multifocally in-
oculated with A and AR Walker
256 (W256) tumor cells. Data
are reported as means ± SEM.
The number of rats in each group
is given in parentheses. MCF =
mean corpuscular fragility. *P <
0.01 compared to control on day
10 (paired Student t-test).
Figure 3. Changes in osmotic
fragility induced in normal donor
RBC by incubation (30 min at
37ºC) with plasma obtained from
controls, Walker 256 (W256) A
tumor bearers and W256 AR tu-
mor bearers at different inter-
vals after tumor inoculation.
Data are reported as means ±
SEM. The number of experi-
ments is given in parentheses.
MCF = mean corpuscular fragil-
ity. *P < 0.05 compared to con-
trol on day 10 (ANOVA followed
by the post hoc Dunnett test).
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5.2 ± 0.4 g/100 ml in A tumor bearers and from
15.2 ± 0.5 to 6.7 ± 0.8 g/100 ml in AR tumor
bearers. In control splenectomized rats, no
significant changes were observed in hemo-
globin levels (Figure 1).
Changes in RBC osmotic fragility induced by
tumor growth
There was no significant change in the
fresh RBC osmotic fragility of A tumor bear-
ers in spite of the pronounced degree of
anemia, while in AR tumor bearers a marked
58% rise in RBC osmotic fragility was ob-
served on day 10 after inoculation (Figure
2). The increase in RBC osmotic fragility in
these splenectomized animals usually started
at about day 8 and reached a maximum (with
intravascular hemolysis) around day 10, when
the animals were sacrificed.
Changes in RBC osmotic fragility induced by
unfractioned plasma and plasma fractions
from A and AR tumor bearers
Only plasma samples obtained on day 10
from AR tumor bearers were able, after incu-
bation at 37ºC, to induce a significant in-
crease in osmotic fragility of fresh RBC
from normal donor rats (Figure 3). A full
effect of increase in osmotic fragility was
already observed after 30 min of incubation
at 37ºC and maintained from then on up to
240 min (data not shown).
Regarding the plasma fractions, four days
after inoculation, P60 obtained from A and
AR plasmas induced an increase in RBC
osmotic fragility of fresh RBC from normal
donor rats. On day 10, this activity disap-
peared in the plasma of the A tumor bearers,
but remained in the plasma of the AR tumor-
bearing rats (Figure 4). In addition, an im-
portant activity increasing RBC osmotic fra-
gility appeared on day 10 in the S60 fraction
from AR tumor bearers. This new activity
precipitated completely at 80% ammonium
sulfate saturation; no RBC osmotic fragility
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increasing activity could be detected in the
S80 fraction (Figure 4). Full effects were
already detectable after a 30-min incubation
and therefore the results obtained after 120-
and 240-min incubation have not been in-
cluded.
Figure 4. Changes in osmotic
fragility induced in normal do-
nor RBC by incubation with to-
tal plasma and fractions from
controls and from Walker 256
(W256) A and W256 AR tumor
bearers obtained at different
times after tumor inoculation.
Data are reported as means ±
SEM. The number of experi-
ments is given in parentheses.
P60: precipitate from 60% am-
monium sulfate saturation; S60:
supernatant from 60% ammo-
nium sulfate saturation; P60-80:
precipitate from 60-80% ammo-
nium sulfate saturation. MCF,
mean corpuscular fragility.
*P < 0.05 compared to total
plasma (ANOVA followed by the
post hoc Dunnett test).
*
*
*
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Autopsy
No evidence of metastasis was found in
any of the experimental animals, nor signifi-
cant tissue invasion or bleeding that could
have masked the present observations.
Discussion
Cancer anemia
Cancer anemia is classified as an anemia
of chronic diseases, whose pathogenic mech-
anism has been difficult to establish. Bone
marrow production of RBC is usually slightly
increased but insufficient to compensate for
a moderately increased RBC destruction (14-
17). At present, there are no clear explana-
tions for either phenomenon, i.e., bone mar-
row relative insufficiency and increased RBC
destruction. It has been suggested that the
activation of the immune and inflammatory
systems through the increasing levels of pro-
inflammatory cytokines such as interleukins
1 and 6, TNF-α and INF-δ would induce iron
retention by the reticuloendothelial system,
gastrointestinal tract and liver, therefore ex-
erting an inhibitory effect on erythroid pre-
cursors (18-20). The erythropoietin produc-
tion and bone marrow response to it are
decreased in cancer anemia (4,18,20,21) and
treatment with recombinant erythropoietin
has been reported to be only of temporary
help (14,22). Macro- and/or microscopic al-
terations of bone marrow have long been
ruled out as factors involved in cancer ane-
mia in humans (23) and rats (4). In the
terminal stage of cancer, RBC are rapidly
destroyed, even transfused ones, at a rate of
up to five times the physiological rate, with-
out an increase in RBC osmotic fragility (8).
This terminal anemia is not temporary but
continues to increase with a very high corre-
lation (r2 = 0.86) with the other severe sys-
temic effects involved in terminal general
failure (8). Development of hemolytic ane-
mia associated with increased RBC osmotic
fragility is not frequent in cancer and has
been associated with a) autoimmune anti-
bodies, b) microangiopathic alterations, and
c) chemotherapy (24,25).
The present study emphasizes the com-
plexity of the mechanisms involved in ane-
mia induced by cancer. We had previously
reported that in intact rats bearing the pro-
gressive A variant of the W256 cancer the
rapid terminal destruction of RBC was asso-
ciated with a decrease or no change in RBC
osmotic fragility (8). In contrast, rats inocu-
lated with the AR tumor variant systemati-
cally developed a temporary anemia associ-
ated with a marked increase in RBC osmotic
fragility at the beginning of tumor regres-
sion. This anemia progressed and rapidly led
to lethal intravascular hemolysis only in sple-
nectomized rats, a model used in order to
amplify the effect we wanted to study in the
present investigation. Chemotherapy was not
employed in the present study and the char-
acteristic fragments of RBC present in mi-
croangiopathic anemia were not found in the
morphological studies performed on blood.
The hemolytic nature of the anemia, its early
and temporary manifestation in intact AR
tumor bearers and the apparent role of the
spleen in modulating it raise the possibility
that immunoglobulins associated with an in-
itial polyclonal immune response to the tu-
mor could be involved in its mechanism,
perhaps signaling the elaboration of a further
step toward the development of an adaptive
host immune response, whose success, how-
ever, is still not guaranteed.
Development of anemia and changes in RBC
osmotic fragility induced by tumor growth
The development of anemia among A
and AR tumor-bearing rats was highly syn-
chronized. It started about day 4 and was
marked at day 10 (see Figure 1). These re-
sults agree with the usual kinetics of the
development of anemia induced by multifo-
cal inoculation of W256 tumor cells in intact
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rats, whose RBC are destroyed at about five
times the physiological rate around the 10th
day, as previously reported (8). Since sple-
nectomized rats were used in the present
experiments, this marked degree of anemia
indicates that the spleen may not be the only
site of RBC destruction in rats bearing the
W256 tumor.
Ten days after inoculation a marked in-
crease in osmotic fragility was detected only
in RBC obtained from the animals receiving
the AR variant of the W256 tumor cells
(Figure 2). The presence of this activity only
in plasma from rats bearing the immuno-
genic AR variant is consistent with the idea
discussed previously that this hemolytic ac-
tivity could reflect some kind of immunore-
sponse, maybe immunoglobulin production,
against the W256 tumor. Contrary to the just
temporary increase in RBC osmotic fragility
observed in the intact AR tumor bearers, the
increase in RBC osmotic fragility in the sple-
nectomized AR tumor bearers progressed
and fatally evolved to intravascular hemoly-
sis and ultimately death, had the animals not
been sacrificed in advance. These observa-
tions confirmed preliminary experiments in-
dicating an exacerbation of the increase in
RBC osmotic fragility in splenectomized
W256 AR tumor bearers, and supported the
use of splenectomized animals in the experi-
ments that followed this study in order to
isolate the putative substance that increases
RBC osmotic fragility. In non-tumor-bear-
ing rats, as can be seen in Figures 1 and 2,
splenectomy by itself induced no significant
degree of anemia or alteration of RBC os-
motic fragility up to day 10 postinoculation
(days 11-12 postsplenectomy; see Material
and Methods).
Another interesting observation shown
in Figures 1 and 2 is that the anemia induced
by the W256 tumor cells was independent of
the changes in RBC osmotic fragility, since
the degree of anemia found in the splenecto-
mized A tumor bearers, whose RBC showed
no significant changes in osmotic fragility,
was even higher than that observed in the
AR tumor bearers, whose RBC osmotic fra-
gility were markedly increased. In a previous
study, intact rats inoculated with the W256
A tumor cells presented a decrease in RBC
osmotic fragility associated with tumor
growth (8). The lack of significant changes
in RBC osmotic fragility in A tumor bearers
observed in these experiments may be re-
lated to the fact that splenectomized animals
were used in the latter experiments. These
observations indicate the complexity of the
mechanisms involved in anemia induced by
cancer.
Changes in RBC osmotic fragility induced by
plasma from W256 A and AR tumor bearers
Consistent with the increase in RBC os-
motic fragility observed in animals 10 days
after inoculation with the AR tumor variant,
only the plasma from AR tumor bearers was
able to increase the RBC osmotic fragility of
normal non-tumor-bearing donors under in-
cubation at 37ºC (Figure 3). These observa-
tions confirmed our preliminary observa-
tions and indicate that factors present in AR
plasma may be responsible for the increase
in RBC osmotic fragility observed in the
animals bearing this regressive tumor vari-
ant.
Changes in RBC osmotic fragility induced by
plasma fractions from A and AR tumor bearers
When RBC from normal non-tumor-bear-
ing donors were incubated with plasma frac-
tions from A and AR tumor bearers, two
kinds of activities increasing RBC osmotic
fragility could be observed (Figure 4): an
early activity precipitating at 60% ammo-
nium sulfate saturation, detected on day 4 in
the plasma of both A and AR tumor bearers,
and a later activity precipitating at 80% am-
monium sulfate saturation, detected on day
10 only in the plasma of rats bearing the AR
tumor variant. Interestingly enough, the early
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activity disappeared on day 10 from the
plasma of the W256 A tumor bearers, while
persisting in the plasma of the animals bear-
ing the AR tumor variant.
These results suggest that, during W256
tumor growth, compounds with a high mo-
lecular weight, which are able to increase
RBC osmotic fragility in A and AR tumor
bearers, were produced. These molecules
could be part of an initial immune response
against the tumor, which would be sustained
only by the animals bearing the AR tumor
variant. Furthermore, only the AR bearers
were able to produce other additional mol-
ecules of smaller molecular weight with simi-
lar activities, suggesting the initiation of a
possible adaptive immune response against
the W256 cancer. The biochemical nature of
these molecules is not clear, but their pro-
duction kinetics, salt solubility characteris-
tics and hemolytic activity resemble those of
the immunoglobulin superfamily involved
in immune responses.
In conclusion, changes in osmotic fragil-
ity of RBC occur during growth of the W256
tumor, with early and temporary increase in
osmotic fragility being characteristic of the
immunogenic AR variant. Products associ-
ated with this activity can be isolated from
plasma of tumor bearers, whose chemical
nature and pathophysiological role deserve
further studies.
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